Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 2
2015 1
2016 3
2017 5
2018 5
2019 2
2020 1
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Reply to Ugo De Giorgi, Vincenza Conteduca, and Emanuela Scarpi's Letter to the Editor re: Marzia Del Re, Elisa Biasco, Stefania Crucitta, et al. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. Eur Urol 2017;71:680-7.
Del Re M, Biasco E, Crucitta S, Derosa L, Rofi E, Orlandini C, Miccoli M, Galli L, Falcone A, Jenster GW, van Schaik RH, Danesi R. Del Re M, et al. Among authors: biasco e. Eur Urol. 2018 Jan;73(1):e11-e12. doi: 10.1016/j.eururo.2017.07.034. Epub 2017 Aug 9. Eur Urol. 2018. PMID: 28801127 No abstract available.
Pharmacogenetics of androgen signaling in prostate cancer: Focus on castration resistance and predictive biomarkers of response to treatment.
Del Re M, Crucitta S, Restante G, Rofi E, Arrigoni E, Biasco E, Sbrana A, Coppi E, Galli L, Bracarda S, Santini D, Danesi R. Del Re M, et al. Among authors: biasco e. Crit Rev Oncol Hematol. 2018 May;125:51-59. doi: 10.1016/j.critrevonc.2018.03.002. Epub 2018 Mar 6. Crit Rev Oncol Hematol. 2018. PMID: 29650277 Review.
Sequencing radium 223 and other life-prolonging agents in castration-resistant prostate cancer patients.
Caffo O, Frantellizzi V, Monari F, Sbrana A, Costa RP, Pinto C, Tucci M, Baldari S, Facchini G, Bortolus R, Alongi F, Alongi P, Palermo A, Fanti S, Biasco E, Murabito A, Filice A, Zichi C, Pignata S, Borsatti E, Salgarello M, Spada M, Cortesi E, Vincentis G. Caffo O, et al. Among authors: biasco e. Future Oncol. 2021 Mar;17(7):807-815. doi: 10.2217/fon-2020-0391. Epub 2021 Jan 29. Future Oncol. 2021. PMID: 33508980
Activity and safety of metronomic cyclophosphamide in the modern era of metastatic castration-resistant prostate cancer.
Caffo O, Facchini G, Biasco E, Ferraù F, Morelli F, Donini M, Buttigliero C, Calvani N, Guida A, Chiuri VE, Basso U, Mucciarini C, Conteduca V, Rossetti S, Veccia A, Maines F, Kinspergher S, De Giorgi U. Caffo O, et al. Among authors: biasco e. Future Oncol. 2019 Apr;15(10):1115-1123. doi: 10.2217/fon-2018-0715. Epub 2019 Mar 19. Future Oncol. 2019. PMID: 30887825
The effect of a treatment delay on outcome in metastatic renal cell carcinoma.
Iacovelli R, Galli L, De Giorgi U, Porta C, Nolè F, Zucali P, Sabbatini R, Mosca A, Atzori F, Santini D, Facchini G, Fornarini G, Buti S, Massari F, Masini C, Ricotta R, Biasco E, Lolli C, Gri N, Verri E, Miggiano C, Vitale MG, Tortora G. Iacovelli R, et al. Among authors: biasco e. Urol Oncol. 2019 Aug;37(8):529.e1-529.e7. doi: 10.1016/j.urolonc.2019.03.005. Epub 2019 Mar 29. Urol Oncol. 2019. PMID: 30935843
The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma.
Iacovelli R, Cossu Rocca M, Galli L, Sabbatini R, De Giorgi U, Santini D, Facchini G, Mosca A, Atzori F, Zucali P, Fornarini G, Massari F, Buti S, Ricotta R, Masini C, Toscani I, Biasco E, Guida A, Lolli C, De Lisi D, Rossetti S, Terrone C, Scartozzi M, Miggiano C, Pastorino A, Bersanelli M, Carlo-Stella G, Pinto C, Nobili E, Nolè F, Tortora G, Porta C. Iacovelli R, et al. Among authors: biasco e. Anticancer Drugs. 2018 Aug;29(7):705-709. doi: 10.1097/CAD.0000000000000632. Anticancer Drugs. 2018. PMID: 29846246
Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer patients sequentially treated with abiraterone acetate and RADIUM-223.
Caffo O, Frantellizzi V, Tucci M, Galli L, Monari F, Baldari S, Masini C, Bortolus R, Facchini G, Alongi P, Agostini S, Zichi C, Biasco E, Fanti S, Pignata S, Filice A, Borsatti E, Rossetti S, Spada M, Cortesi E, De Vincentis G. Caffo O, et al. Among authors: biasco e. Eur J Nucl Med Mol Imaging. 2020 Oct;47(11):2633-2638. doi: 10.1007/s00259-020-04796-w. Epub 2020 Apr 5. Eur J Nucl Med Mol Imaging. 2020. PMID: 32249345
Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: a multicenter retrospective analysis.
Santini D, Ratta R, Pantano F, De Lisi D, Maruzzo M, Galli L, Biasco E, Farnesi A, Buti S, Sternberg CN, Cerbone L, Di Lorenzo G, Spoto S, Sterpi M, De Giorgi U, Berardi R, Torniai M, Camerini A, Massari F, Procopio G, Tonini G. Santini D, et al. Among authors: biasco e. Oncotarget. 2017 Aug 7;8(59):100708-100716. doi: 10.18632/oncotarget.20022. eCollection 2017 Nov 21. Oncotarget. 2017. PMID: 29246014 Free PMC article.
Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer.
Iacovelli R, Cossu Rocca M, Galli L, De Giorgi U, Sabbatini R, Santoni M, Mosca A, Fornarini G, Massari F, Masini C, Bersanelli M, Biasco E, Lolli C, Guida A, Berardi R, Terrone C, Pastorino A, Ardizzoni A, Pinto C, Buti S, Nolè F, Tortora G. Iacovelli R, et al. Among authors: biasco e. Urol Oncol. 2017 Sep;35(9):541.e7-541.e13. doi: 10.1016/j.urolonc.2017.05.007. Epub 2017 May 29. Urol Oncol. 2017. PMID: 28572027
18 results